Breaking News Instant updates and real-time market news.

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06

Axovant Phase 3 Alzheimer's study misses co-primary endpoints

Axovant Sciences announced that the Phase 3 Mindset clinical trial of its investigational drug intepirdine in patients with mild to moderate Alzheimer's disease who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale and by the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale, respectively, compared to patients treated with placebo. In the study, intepirdine was generally well tolerated, the company added. After 24 weeks of treatment, change from baseline in cognition was non-significantly improved in the intepirdine arm versus the placebo arm. In addition, there was essentially no difference between the intepirdine and placebo arms in change from baseline in activities of daily living. Of the endpoints analyzed to date, the only endpoint in which any significant improvement was seen in the intepirdine arm versus the placebo arm was in the first key secondary endpoint, the Clinician Interview-Based Impression of Change plus caregiver interview, or CIBIC-plus. Axovant said, "The Company will work with investigators to conclude the MINDSET open-label extension study. " David Hung, CEO of Axovant, added, "While we are deeply disappointed by these trial results, we also are saddened for the millions of patients and families impacted by Alzheimer's disease. However, we believe that the fight against Alzheimer's and other important areas of unmet need in neurology is too important to be derailed by this setback.... We remain committed to advancing our pipeline." Axovant shares remain halted. They closed yesterday down 6c to $22.59.

AXON Axovant Sciences
$24.25

-0.74 (-2.96%)

07/10/17
JEFF
07/10/17
INITIATION
Target $40
JEFF
Buy
Axovant Sciences initiated with a Buy at Jefferies
Jefferies analyst Michael Yee initiated Axovant Sciences with a Buy and a $40 price target.
07/12/17
OPCO
07/12/17
NO CHANGE
OPCO
Outperform
Axovant Sciences upcoming results may drive valuation upside, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Axovant Sciences faces two substantial binary events including the Phase 3 MINDSET study results at the end of September and the Phase 2 HEADWAY study results in Q4. The combination of these two events could drive up to 100% valuation upside, he contends. Further, the analyst believes the company is positioned to deliver the first new symptomatic Alzheimer's Disease drug approved by the FDA in over a decade. Olson reiterates an Outperform rating on the shares.
09/08/17
EVER
09/08/17
NO CHANGE
Target $30
EVER
Outperform
Axovant Sciences assumed with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer assumed coverage on Axovant Sciences with an Outperform and a $30 price target.
09/14/17
JEFF
09/14/17
NO CHANGE
Target $40
JEFF
Buy
Axovant looks 'very intriguing' at $20 per share, says Jefferies
Jefferies analyst Michael Yee believes the recent selloff in shares of Axovant Sciences presents a "unique" buying opportunity. At around $20 per share, the stock looks "very intriguing," Yee tells investors in a research note. The analyst sees "significant" potential upside, to $40-$100 per share, if the Phase III Alzheimer's data this month is positive. Yee's downside case is $3-$10 per share on negative data. Investors "should and will" buy the large selloff on negative data because CEO David Hung is likely to pivot the company, bring in more assets, and create value "from there pretty quickly," the analyst contends. Yee has a Buy rating on Axovant with a $40 price target. He thinks the Phase III Alzheimer's data has a 50%-60% chance of being positive.

TODAY'S FREE FLY STORIES

WMT

Walmart

$104.78

1.55 (1.50%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Hot Stocks
Breaking Hot Stocks news story on Walmart »

Walmart sees FY19 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

WMT

Walmart

$104.78

1.55 (1.50%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Hot Stocks
Walmart says moving to annual guidance framework with quarterly updates »

Walmart also commented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

SLDB

Solid Biosciences

$24.93

-1.34 (-5.10%)

, SRPT

Sarepta

$64.00

0.86 (1.36%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Initiation
Solid Biosciences, Sarepta initiated  »

Solid Biosciences…

SLDB

Solid Biosciences

$24.93

-1.34 (-5.10%)

SRPT

Sarepta

$64.00

0.86 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

USO

United States Oil Fund

$12.38

0.05 (0.41%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVPT

Travelport

$13.22

0.14 (1.07%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Travelport reports Q4 adj. EPS 35c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 26

    Feb

  • 30

    May

WMT

Walmart

$104.78

1.55 (1.50%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Walmart sees FY19 net sales growth 1.5%-2%, consensus $511.94B »

Sees FY19 effective tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

CDXC

ChromaDex

$5.39

0.01 (0.19%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Hot Stocks
ChromaDex announces two new collaborative human clinical studies on NIAGEN »

ChromaDex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

XOP

SPDR Oil Exploration and Production Fund

$33.92

-0.17 (-0.50%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$83.31

0.37 (0.45%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Medtronic backs FY18 adjusted EPS growth view of 9%-10%, consensus $4.77 »

In fiscal year 2018, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 23

    Mar

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$31.88

0.71 (2.28%)

06:46
02/20/18
02/20
06:46
02/20/18
06:46
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGS

PlayAGS

$19.95

0.11 (0.55%)

06:46
02/20/18
02/20
06:46
02/20/18
06:46
Initiation
PlayAGS initiated  »

PlayAGS initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$23.31

-0.01 (-0.04%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Hot Stocks
Tailored Brands launches three week custom delivery »

Men's Wearhouse and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

TFX

Teleflex

$267.89

2.28 (0.86%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Hot Stocks
Teleflex subsidiary announces FDA cleared new indication for UroLift »

NeoTract, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

  • 01

    Mar

  • 14

    Mar

ADM

Archer Daniels

$43.13

0.265 (0.62%)

, SYT

Syngenta

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Periodicals
ADM, Syngenta settle lawsuit over biotech corn exports to China, Reuters reports »

Archer Daniels Midland…

ADM

Archer Daniels

$43.13

0.265 (0.62%)

SYT

Syngenta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$83.31

0.37 (0.45%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Earnings
Medtronic reports Q3 adjusted EPS $1.17, consensus $1.17 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 23

    Mar

UGAZ

VelocityShares 3x Long Natural Gas ETN

$52.20

-1.3 (-2.43%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.36

1.28 (4.40%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Initiation
PagSeguro Digital initiated  »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$54.90

1.25 (2.33%)

, EGRX

Eagle Pharmaceuticals

$64.78

-0.07 (-0.11%)

06:44
02/20/18
02/20
06:44
02/20/18
06:44
Hot Stocks
Aerie Pharmaceuticals appoints John LaRocca as General Counsel »

Aerie Pharmaceuticals…

AERI

Aerie Pharmaceuticals

$54.90

1.25 (2.33%)

EGRX

Eagle Pharmaceuticals

$64.78

-0.07 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 28

    Feb

  • 05

    Apr

EWZ

MSCI Brazil Index

$45.54

0.03 (0.07%)

06:43
02/20/18
02/20
06:43
02/20/18
06:43
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCMGY

Newcrest Mining

$17.47

-0.87 (-4.74%)

06:43
02/20/18
02/20
06:43
02/20/18
06:43
Upgrade
Newcrest Mining rating change  »

Newcrest Mining upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$71.42

0.32 (0.45%)

06:43
02/20/18
02/20
06:43
02/20/18
06:43
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$36.32

0.18 (0.50%)

06:42
02/20/18
02/20
06:42
02/20/18
06:42
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KIRK

Kirkland's

$11.89

0.69 (6.16%)

06:42
02/20/18
02/20
06:42
02/20/18
06:42
Earnings
Kirkland's sees FY17 EPS 32c-34c, consensus 52c »

Based on Q4 sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$9.09

-0.14 (-1.52%)

06:42
02/20/18
02/20
06:42
02/20/18
06:42
Hot Stocks
Transocean receives approvals, commences acquisition of remaining Songa shares »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Feb

SJB

ProShares Short High Yield

$23.25

-0.0996 (-0.43%)

06:41
02/20/18
02/20
06:41
02/20/18
06:41
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.